October 2, 2024 4:40pm

Not to get ahead of themselves as far as what and when confidence returns to “our” universe

There will be a bounce before earnings season initiates, then it might be time – when LPS (loss-per-share) estimates are beat or just “meat” for consensus and runway expectations

Debt and ATM usage is a concern for me as well as the usual – the ability to finance!

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

 

Wednesday: The Dow closed UP +39.55 points or +0.09%, the S&P closed UP +0.79 points or +0.01% while the Nasdaq closed UP +14.76 points or +0.08%

  • Indexes continued danced around their flatlines entering the final hour of trading.
  • The CBOE Volatility Index (VIX) the fear gauge, pulled back after a spike on Tuesday.

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

  • US private payroll numbers beat expectations in September, according to the latest ADP report. The data shows that 143,000 jobs were added in the private sector last month, surpassing the projected 125,000 jobs— a significant increase from August's reported 99,000 jobs.

Wednesday’s advance/decline line at the open was negative with 11 incliners, 20 decliners and 4 flats; ending with a negative close at the close of 15 incliner, 17 decliners and 3 flats

  • Sector eked out a slight gain, as the oversold got grabbed-up …
  • But the overall trend is to the upside

Metrics:  Wednesday, the IBB was up +0.02% and the XBI was up +0.12% while the VIX was down -0.34 points or -1.77% at 18.92.

 

Wednesday’s Closing Down (10 of 17):

  • Alnylam Pharmaceuticals (ALNY -$4.51 after Tuesday’s +$1.03 after Monday’s +$0.12),
  • Ultragenyx Pharmaceuticals (RARE -$0.96 after Tuesday’s +$0.96 after Monday’s +$1.12),
  • Intellia Therapeutics (NTLA -$0.65 after Tuesday’s -$1.35 after Monday’s -$0.45),
  • Brainstorm Cell Therapeutics (BCLI -$0.61),
  • Regenxbio (RGNX -$0.29),
  • Agenus (AGEN -$0.25),
  • AxoGen (AXGN -$0.17 after Tuesday’s +$0.29 after Monday’s +$0.23),
  • Solid Biosciences (SLDB -$0.16),
  • Fate Therapeutics (FATE -$0.14),
  • MiMedx (MDXG -$0.10),

Flat (3):

  • Bellicum Pharmaceuticals (BLCM)
  • Harvard Apparatus RT (OTCQB: HRGN)
  • Homology Medicine (FIXX)

Wednesday’s Closing Up (10 of 15):

  • Blueprint Medicine (BPMC +$0.76 after Tuesday’s -$2.50),
  • Vericel (VCEL +$0.65 after Tuesday’s -$2.20 after Monday’s -$0.94),
  • Mesoblast (MESO +$0.49 after Tuesday’s +$0.10 after Monday’s +$0.57),
  • Ionis Pharmaceuticals (IONS +$0.31 after Tuesday’s -$0.99 after Monday’s -$0.79),
  • Adverum Therapeutics (ADVM +$0.23 after Tuesday’s -$0.43 after Monday’s +$0.08),
  • BioLife Solutions (BLFS +$0.15 after Tuesday’s -$0.90 after Monday’s +$0.70),
  • Generation Bio (GBIO +$0.15),
  • CRISPR Therapeutics (CRSP +$0.13 after Tuesday’s -$1.40 after Monday’s -$0.34),
  • Beam Therapeutics (BEAM +$0.09 after Tuesday’s -$1.09 after Monday’s -$0.55),
  • LENZ Therapeutics (LENZ +$0.09 after Tuesday’s -$0.94 after Monday’s -$0.30),

 

RegMed Investors’ (RMi) pre-open: “headwinds, it ain’t over as Q4 begins. After the 10/1 global tension and U.S. death, damage and port strike “events”, archive a barely aftermarket response. Although … volatility is opportunity for “some” bargain hunting as cell and gene therapy earnings won’t be released for weeks.” … https://www.regmedinvestors.com/articles/13638

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:  Q4/24

  • 2 sessions close negative

Q3/24

  • September – 10 positive and 11 negative closes
  • August: 1 neutral, 10 positive and 11 negative closes
  • July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes

 

The BOTTOM LINE: I keep writing about uncertainty and skepticism … and coming realities.

  • One thought and warning ... If Israel hit/bomb the Iranian oil fields - all market BETS are ... OFF!

 

Love the quote: "Is it time to sell Rosh Hashanah, buy Yom Kippur?"

  • Investors looking for a strategy to playing the market over the next 10 days may want to take a cue from an age-old Wall Street adage.
  • The saying — known as sell Rosh Hashanah, buy Yom Kippur — suggests that investors should sell into the Jewish new year and buy into the day of atonement.
  • The start of the Jewish new year begins Wednesday evening, with Yom Kippur starting Oct. 11. <Samantha Subin – CNBC>

 

Markets dived escalating volatility:

  • US stocks slid – AGAIN -- on Wednesday after Iran fired (Tuesday) over 181 ballistic missiles at Israel, pushing oil prices for West Texas Intermediate and Brent to their biggest increases in nearly a year.
  • A strike by dockworkers began on the East and Gulf coasts, threatens to halt the flow of half the US's ocean shipping. Some estimates project that a port strike could cost the US $5 billion per day. She notes that the last port strike was in 1977 and lasted for 45 days.
  • Hurricane Helene damage and deaths grow through-out many southern states.
  • After the debate, the White House’s response to all these above “situations” with the upcoming election also will explain ... the mixed signals coming toward the market

 

The top three (3) performing in the session: 

  • Wednesday: Blueprint Medicine (BPMC), Vericel (VCEL) and Mesoblast (MESO)
  • Tuesday: Ultragenyx Pharmaceuticals (RARE), Alnylam Pharmaceuticals (ALNY) and AxoGen (AXGN)
  • Monday: BioLife Solutions (BLFS), Mesoblast (MESO) and Ultragenyx Pharmaceuticals (RARE)

The worst three (3) in the session: 

  • Wednesday: Alnylam Pharmaceuticals (ALNY), Ultragenyx Pharmaceuticals (RARE) and Intellia Therapeutics (NTLA)
  • Tuesday: Blueprint Medicine (BPMC), Vericel (VCEL) and Intellia Therapeutics (NTLA)
  • Monday: Vericel (VCEL), Ionis Pharmaceuticals (IONS) and BEAM Therapeutics (BEAM)

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.